⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 9, 2026Neurology

Eculizumab Efficacy and Safety in Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review (P2-2.013)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To summarize available evidence regarding the efficacy and safety of Eculizumab in patients diagnosed with Neuromyelitis Optica Spectrum Disorder.
Conducted a systematic review on studies involving Eculizumab in NMOSD patients.
Analyzed efficacy and safety outcomes reported in the identified studies.
Eculizumab demonstrates significant efficacy in reducing relapse rates compared to placebo.
Safety profile indicates a manageable risk of adverse events in treated patients.

Implication

Systematic review summarizes evidence on Eculizumab efficacy and safety in NMOSD, indicating potential benefits for patients.

Abstract

In this Systematic Review (SR) we aim to summarize the current available evidence on Eculizumab efficacy and safety in patients with NMOSD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roba Al Shouli (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f05627e https://doi.org/10.1212/wnl.0000000000216995

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Eculizumab in the treatment of neuromyelitis optica spectrum disorder2025
2Complement C5 inhibitor as a rescue therapy for acute NMOSD attacks: a multicenter retrospective cohort study in ChinaCohort Study · 2026
3Eculizumab for the acute attack of neuromyelitis optica spectrum disorder2025 · 8 citations
4Efficacy of Eculizumab in Acute Refractory Pediatric Neuromyelitis Optica: A Case Report (P11-14.012)2024 · 2 citations
5Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder AttacksRetrospective Study · 2026 · 8 citations